Navigating Multiple Myeloma: A more positive journey for patients

Increasing number of patients
Increased awareness, diagnostics and an aging population has led to more frequent diagnosis of Multiple Myeloma.

Increasingly complex regimens in trials
The number of agents in a treatment regimen in clinical development has increased from 2 (doublets) to 3 (triplets) over the last 20 years.

Increasingly efficacious therapies
Therapy efficacy (e.g. Objective Response Rate (ORR)) has risen across first, second and third lines of therapy over the last 10 years.

Increasing survival
Higher proportions of patients are surviving longer compared to 20 years ago.

For more information on data sources, please contact us.